Literature DB >> 7474071

Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5.

C Caravokyri1, K N Leppard.   

Abstract

The human adenovirus type 5 capsid is composed of a number of distinct polypeptides. It has been shown previously that one of these, polypeptide IX (pIX), is not absolutely required for the production of viable virus. However, viruses lacking this polypeptide have a significantly reduced packaging limit and, in the one case studied, also show a thermolabile virion phenotype. This report describes the use of eukaryotic episomal vectors based on the Epstein-Barr virus replicon to generate cells which stably express pIX. These cells provide pIX that is efficiently incorporated into virions that are genetically pIX-; such enhanced thermostability. These cells have also been used to isolate a genetically pIX- virus having a genome of length some 2.3 kbp in excess of the previously defined packaging limit for pIX- virus; the resulting virions have wild-type thermostability. These cells expand the theoretical capacity of adenovirus vectors for foreign DNA to around 9.2 kbp and may therefore be useful in gene therapy applications in which vector capacity is limiting.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474071      PMCID: PMC189571     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  A thermolabile mutant of adenovirus 5 resulting from a substitution mutation in the protein VIII gene.

Authors:  G Q Liu; L E Babiss; F C Volkert; C S Young; H S Ginsberg
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

5.  The adenovirus type 5 E1A transcriptional control region contains a duplicated enhancer element.

Authors:  P Hearing; T Shenk
Journal:  Cell       Date:  1983-07       Impact factor: 41.582

6.  A monoclonal antibody detecting the adenovirus type 5-E1b-58Kd tumor antigen: characterization of the E1b-58Kd tumor antigen in adenovirus-infected and -transformed cells.

Authors:  P Sarnow; C A Sullivan; A J Levine
Journal:  Virology       Date:  1982-07-30       Impact factor: 3.616

7.  Isolation of mutants of an animal virus in bacteria.

Authors:  K W Peden; J M Pipas; S Pearson-White; D Nathans
Journal:  Science       Date:  1980-09-19       Impact factor: 47.728

8.  Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX.

Authors:  W W Colby; T Shenk
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

9.  Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein.

Authors:  N C Reich; P Sarnow; E Duprey; A J Levine
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

10.  Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy.

Authors:  P L Stewart; S D Fuller; R M Burnett
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

View more
  14 in total

1.  Interaction of the adenovirus IVa2 protein with viral packaging sequences.

Authors:  W Zhang; M J Imperiale
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Adenovirus late-phase infection is controlled by a novel L4 promoter.

Authors:  Susan J Morris; Gillian E Scott; Keith N Leppard
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

3.  The coiled-coil domain of the adenovirus type 5 protein IX is dispensable for capsid incorporation and thermostability.

Authors:  Jort Vellinga; Diana J M van den Wollenberg; Stephanie van der Heijdt; Martijn J W E Rabelink; Rob C Hoeben
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX.

Authors:  Michael P Marsh; Samuel K Campos; Matthew L Baker; Christopher Y Chen; Wah Chiu; Michael A Barry
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

5.  Adenovirus serotype 5 L4-22K and L4-33K proteins have distinct functions in regulating late gene expression.

Authors:  Susan J Morris; Keith N Leppard
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

6.  The product of the adenovirus intermediate gene IX is a transcriptional activator.

Authors:  P Lutz; M Rosa-Calatrava; C Kedinger
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  The complete DNA sequence and genomic organization of the avian adenovirus CELO.

Authors:  S Chiocca; R Kurzbauer; G Schaffner; A Baker; V Mautner; M Cotten
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

8.  Development and assessment of human adenovirus type 11 as a gene transfer vector.

Authors:  Daniel Stone; Shaoheng Ni; Zong-Yi Li; Anuj Gaggar; Nelson DiPaolo; Qinghua Feng; Volker Sandig; André Lieber
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene.

Authors:  J Schaack; X Guo; S J Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

10.  Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors.

Authors:  A I Michou; H Lehrmann; M Saltik; M Cotten
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.